Market Cap 2.84B
Revenue (ttm) 0.00
Net Income (ttm) -148.96M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 349,492
Avg Vol N/A
Day's Range N/A - N/A
Shares Out 123.68M
Stochastic %K 24%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-ag...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 317 0290
Address:
180 Third Avenue, 4th Floor, Waltham, United States
biolover
biolover May. 11 at 2:48 PM
$VKTX looking at $KLRA and $GPCR volumes last few days. All day trading and price manipulation. Not serious new investors. A lot of VK is market makers as well
0 · Reply
JohnnyVacs
JohnnyVacs May. 1 at 4:10 PM
$VKTX $KLRA Is the much better and safer buy here! Management actually cares! BL is actually bearish on his own company. All he wants is more option compensation!
0 · Reply
JohnnyVacs
JohnnyVacs Apr. 29 at 7:59 PM
$VKTX $KLRA About to pass VIKING THERAPEUTICS Market Cap. Crazy times.
1 · Reply
PlutoAnalyses
PlutoAnalyses Apr. 29 at 5:56 PM
$ABBV CMO affirmed co interest in obesity agents that augment weight loss and maintain tolerability. Its an interesting spot for $VKTX because they are such a gread target on paper, but an acquisition would be really expensive since they have funding money and thus leverage other companies wouldnt have. $KLRA might be a bit early in development compared to VKTX so VKTX makes most sence, but its going to be expensive. Curious about Vikings future, follow me to stay up to date. I will publish more articles on VKTX's future catalysts.
0 · Reply
NYG4ever
NYG4ever Apr. 24 at 7:47 PM
$KLRA mega dump
0 · Reply
Bagholding_VKTX
Bagholding_VKTX Apr. 23 at 12:36 PM
$VKTX Just noticed something on $KLRA 's investor relations website. When you are in the SEC filings section and try to filter, there is a category called "Mergers & Acquisitions". Viking does not have this category. What this means for me is the following: I believe KLRA's management did this IPO with the goal of being more transparent with their financial information and promote an acquisition. Thus, I believe KLRA's management will want to sell, even if the price is lower than what it could be, similar to MTSR. Viking is the opposite, as we all know, management wants the highest that it can possibly get because they believe that VK2735 is the best in everything, which I absolutely agree on. However, based on this, I will also be buying some KLRA shares because I believe they could be acquired at a smaller premium, like MTSR. This does not change the Viking thesis, I still believe an acquisition in the 30-40B range is coming.
3 · Reply
MorganHoratio
MorganHoratio Apr. 18 at 12:31 PM
$KLRA: Clinical‑stage biopharma, speculative “unwritten story,” but liquidity is a risk. $AVEX: Cancer drug developer with upcoming data readouts — early pattern looks like HOOD. $NBIS: AI infrastructure play, strong narrative but fierce competition — watch for margin bottom. $HIMS: Telehealth + consumer brand, stable subs, but valuation is no longer cheap — more mid‑term hold. $ONDS: Radar/communication + defense/drone, highly volatile, event‑driven.
4 · Reply
STOCKINSIGHT69
STOCKINSIGHT69 Apr. 18 at 12:03 PM
I called $HOOD early as a high-upside play — still tracking, but I’m always hunting for the next asymmetric setup. Current watchlist (high risk / high reward focus): $KLRA → Clinical-stage biotech. Pure speculation here — “story still forming.” Low liquidity = position sizing is key. $AVEX → Oncology pipeline + upcoming data catalysts. Early structure reminds me of pre-move setups — watching closely. $NBIS → AI infra exposure. Strong narrative tailwind, but margins + competition will decide if this re-rates. HIMS → Telehealth + consumer brand. Solid subscription model, but not cheap anymore. More swing/position trade vs breakout. ONDS → Defense + drone tech. Volatile, headline-driven — can move FAST both ways. This is not about certainty — it’s about risk/reward and timing. I’m lining up my next potential 10x candidate — will share soon. Stay selective. The market rewards positioning, not chasing.
2 · Reply
Latest News on KLRA
Kailera Therapeutics initiated with a Buy at TD Cowen

2026-05-12T09:37:06.000Z - 1 day ago

Kailera Therapeutics initiated with a Buy at TD Cowen


Kailera Therapeutics initiated with a Buy at Jefferies

2026-05-12T09:06:18.000Z - 1 day ago

Kailera Therapeutics initiated with a Buy at Jefferies


Kailera Therapeutics 39.06M share IPO priced at $16.00

2026-04-17T00:05:37.000Z - 26 days ago

Kailera Therapeutics 39.06M share IPO priced at $16.00


Kailera Therapeutics files for US IPO

Mar 27, 2026, 4:15 PM EDT - 6 weeks ago

Kailera Therapeutics files for US IPO


Kailera Therapeutics IPO Registration Document (S-1)

Mar 27, 2026, 4:02 PM EDT - 6 weeks ago

Kailera Therapeutics IPO Registration Document (S-1)


biolover
biolover May. 11 at 2:48 PM
$VKTX looking at $KLRA and $GPCR volumes last few days. All day trading and price manipulation. Not serious new investors. A lot of VK is market makers as well
0 · Reply
JohnnyVacs
JohnnyVacs May. 1 at 4:10 PM
$VKTX $KLRA Is the much better and safer buy here! Management actually cares! BL is actually bearish on his own company. All he wants is more option compensation!
0 · Reply
JohnnyVacs
JohnnyVacs Apr. 29 at 7:59 PM
$VKTX $KLRA About to pass VIKING THERAPEUTICS Market Cap. Crazy times.
1 · Reply
PlutoAnalyses
PlutoAnalyses Apr. 29 at 5:56 PM
$ABBV CMO affirmed co interest in obesity agents that augment weight loss and maintain tolerability. Its an interesting spot for $VKTX because they are such a gread target on paper, but an acquisition would be really expensive since they have funding money and thus leverage other companies wouldnt have. $KLRA might be a bit early in development compared to VKTX so VKTX makes most sence, but its going to be expensive. Curious about Vikings future, follow me to stay up to date. I will publish more articles on VKTX's future catalysts.
0 · Reply
NYG4ever
NYG4ever Apr. 24 at 7:47 PM
$KLRA mega dump
0 · Reply
Bagholding_VKTX
Bagholding_VKTX Apr. 23 at 12:36 PM
$VKTX Just noticed something on $KLRA 's investor relations website. When you are in the SEC filings section and try to filter, there is a category called "Mergers & Acquisitions". Viking does not have this category. What this means for me is the following: I believe KLRA's management did this IPO with the goal of being more transparent with their financial information and promote an acquisition. Thus, I believe KLRA's management will want to sell, even if the price is lower than what it could be, similar to MTSR. Viking is the opposite, as we all know, management wants the highest that it can possibly get because they believe that VK2735 is the best in everything, which I absolutely agree on. However, based on this, I will also be buying some KLRA shares because I believe they could be acquired at a smaller premium, like MTSR. This does not change the Viking thesis, I still believe an acquisition in the 30-40B range is coming.
3 · Reply
MorganHoratio
MorganHoratio Apr. 18 at 12:31 PM
$KLRA: Clinical‑stage biopharma, speculative “unwritten story,” but liquidity is a risk. $AVEX: Cancer drug developer with upcoming data readouts — early pattern looks like HOOD. $NBIS: AI infrastructure play, strong narrative but fierce competition — watch for margin bottom. $HIMS: Telehealth + consumer brand, stable subs, but valuation is no longer cheap — more mid‑term hold. $ONDS: Radar/communication + defense/drone, highly volatile, event‑driven.
4 · Reply
STOCKINSIGHT69
STOCKINSIGHT69 Apr. 18 at 12:03 PM
I called $HOOD early as a high-upside play — still tracking, but I’m always hunting for the next asymmetric setup. Current watchlist (high risk / high reward focus): $KLRA → Clinical-stage biotech. Pure speculation here — “story still forming.” Low liquidity = position sizing is key. $AVEX → Oncology pipeline + upcoming data catalysts. Early structure reminds me of pre-move setups — watching closely. $NBIS → AI infra exposure. Strong narrative tailwind, but margins + competition will decide if this re-rates. HIMS → Telehealth + consumer brand. Solid subscription model, but not cheap anymore. More swing/position trade vs breakout. ONDS → Defense + drone tech. Volatile, headline-driven — can move FAST both ways. This is not about certainty — it’s about risk/reward and timing. I’m lining up my next potential 10x candidate — will share soon. Stay selective. The market rewards positioning, not chasing.
2 · Reply